In the News

AARC Supports Orphan Drug Legislation

Bookmark and Share

August 28, 2009

The AARC is officially behind legislation introduced into Congress by Rep. Kenny Marchant (R-TX) that’s aimed at allowing Medicaid programs to continue to cover eligible individuals who have extremely high annual costs ( over $200,000 per year) associated with the lifelong need for orphan drugs. This would allow these individuals who are currently on Medicaid to be employed and be productive members of their community.

As respiratory therapists know, people suffering from the inherited form of COPD, Alpha-1 Antitrypsin Deficiency, can incur costs of $100,000 or more per year for the FDA-approved treatment for the condition. Rep. Marchant’s bill would go a long way towards ensuring Alpha-1 patients who rely on Medicaid will be able to receive this life-prolonging treatment.

We urge our members to write their member of the House of Representatives in support of HR 1441, The Ryan Dant Healthcare Opportunity Act. To find your member of Congress go to the House website Your member can be found, their official website accessed that will have email and letter contact information.